Rhythm Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$22.4M
Doctors Paid
2,199
Transactions
9,418
2024 Total
$8.0M
Payment Breakdown by Category
Research$21.6M (96.3%)
Food & Beverage$142,510 (0.6%)
Consulting$87,088 (0.4%)
Travel$72,980 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $21.6M | 4,980 | 96.3% |
| Honoraria | $503,401 | 366 | 2.2% |
| Food and Beverage | $142,510 | 3,742 | 0.6% |
| Consulting Fee | $87,088 | 54 | 0.4% |
| Travel and Lodging | $72,980 | 197 | 0.3% |
| Grant | $20,000 | 1 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,503 | 2 | 0.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,187 | 1 | 0.0% |
| Education | $3,173 | 75 | 0.0% |
Payments by Type
Research
$21.6M
4,980 transactions
General
$835,841
4,438 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Trial of Setmelanotide in Acquired Hypothalamic Obesity | $3.4M | 0 | 121 |
| RM-493-034 | $3.0M | 0 | 1,242 |
| EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | $2.5M | 0 | 1,394 |
| RM-493-035 | $2.4M | 0 | 894 |
| RM-493-014 | $2.3M | 0 | 188 |
| RM-493-022 | $2.0M | 0 | 191 |
| DAYBREAK: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway | $993,142 | 0 | 527 |
| RHYTH001_RM 493-040_80072978 | $768,484 | 0 | 42 |
| Long Term Extension Trial of Setmelanotide | $712,574 | 0 | 92 |
| RM-493-030 | $652,003 | 0 | 24 |
| RM-493-037/RM-493-022/RM-493-033 | $402,548 | 0 | 2 |
| RM-493-023 | $394,051 | 0 | 35 |
| RM-493-029 | $359,586 | 0 | 13 |
| RM-493-037/RM-493-022 | $245,882 | 0 | 1 |
| RM-493-014/RM-493-022 | $212,491 | 0 | 6 |
| RM-493-022/ RM-493-014 | $202,835 | 0 | 7 |
| RM-493-033 | $194,556 | 0 | 29 |
| RM-493-037 | $140,511 | 0 | 15 |
| A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity | $140,328 | 0 | 25 |
| RM-493-037/RM-493-033/RM-493-022 | $122,313 | 0 | 2 |
| RM-493-013 | $91,949 | 0 | 35 |
| RM-493-033/RM-493-022 | $83,888 | 0 | 2 |
| Setmelanotide in Pediatric Patients With Rare Genetic Diseases of Obesity | $76,293 | 0 | 19 |
| RM-493-023/RM-493-014 | $30,897 | 0 | 1 |
| RM-493-030/RM-493-022 | $30,469 | 0 | 2 |
| Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Patients With Specific Gene Defects in the MC4R Pathway | $30,331 | 0 | 3 |
| RM-493-037/RM-493-033 | $27,606 | 0 | 3 |
| RM-493-033/RM-493-037 | $25,036 | 0 | 1 |
| RM-493-030/ RM-493-022 | $16,610 | 0 | 1 |
| RM-493-014/RM-493-022/RM-493-037 | $13,012 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Maja Kostic, Md, Phd, MD, PHD | Ophthalmology | Miami, FL | $2,625 | $0 |
| Benjamin Bakall, M.d., Ph.d, M.D., PH.D | Ophthalmology | Phoenix, AZ | $2,516 | $0 |
| Michael Gottschalk, M.d., Ph.d, M.D., PH.D | Pediatric Endocrinology | San Diego, CA | $2,445 | $0 |
| Angela Fitch, Md, MD | Internal Medicine | Boston, MA | $2,415 | $0 |
| Dr. Samareh Hill, M.d., M.p.h, M.D., M.P.H | Pediatrics | Raleigh, NC | $2,268 | $0 |
| Dr. Ken Fujioka, M.d, M.D | Endocrinology, Diabetes & Metabolism | San Diego, CA | $2,196 | $0 |
| Brooke Sweeney, M.d, M.D | Obesity Medicine | Kansas City, MO | $1,874 | $0 |
| Fatima Stanford, Md, Mph, MD, MPH | Internal Medicine | Boston, MA | $1,800 | $0 |
| Mrs. Roohi Kharofa, M.d, M.D | Pediatrics | Cincinnati, OH | $1,746 | $0 |
| Dr. Wendy Chung, Md, MD | Clinical Molecular Genetics | Boston, MA | $1,575 | $0 |
| Lawrence Kirschner, M.d, M.D | Endocrinology, Diabetes & Metabolism | Columbus, OH | $1,350 | $0 |
| Dr. Sonali Malhotra, Md, MD | Pediatric Endocrinology | Boston, MA | $1,344 | $0 |
| Mario Carcamo, Md, MD | Pediatric Endocrinology | Riverside, CA | $1,317 | $0 |
| Stacey Lip, N.p, N.P | Nurse Practitioner | Loma Linda, CA | $1,248 | $0 |
| Evan Nadler, M.d, M.D | Surgery | Philadelphia, PA | $1,192 | $0 |
| Heather Saran, D.o, D.O | Endocrinology, Diabetes & Metabolism | Scottsdale, AZ | $1,184 | $0 |
| Dr. Akhila Ramakrishna, Md, MD | Pediatrics | Iowa City, IA | $1,125 | $0 |
| Dr. Sreedevi Reddy, Md, MD | Endocrinology, Diabetes & Metabolism | Scottsdale, AZ | $1,095 | $0 |
| Rocio Moran, M.d, M.D | Clinical Genetics (M.D.) | Cleveland, OH | $1,000 | $0 |
| Dr. Melinda Pierce, Md, MD | Pediatric Endocrinology | Seattle, WA | $900.00 | $0 |
| Minna Cheng, Md, MD | Student in an Organized Health Care Education/Training Program | Riverside, CA | $855.91 | $0 |
| Andrea Ferenczi, Md, MD | Endocrinology, Diabetes & Metabolism | Scottsdale, AZ | $805.80 | $0 |
| Diva Deleon, M.d, M.D | Pediatrics | Philadelphia, PA | $805.00 | $0 |
| Dr. Silva Arslanian, Md, MD | Specialist | Pittsburgh, PA | $675.00 | $0 |
| Nazrat Mirza, Md, MD | Pediatrics | Washington, DC | $645.63 | $0 |
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. has made $22.4M in payments to 2,199 healthcare providers, recorded across 9,418 transactions in the CMS Open Payments database. In 2024, the company paid $8.0M. The top product by payment volume is Imcivree ($14.1M).
Payments were distributed across 102 medical specialties. The top specialty by payment amount is Pediatric Endocrinology ($144,689 to 140 doctors).
Payment categories include: Food & Beverage ($142,510), Consulting ($87,088), Research ($21.6M), Travel & Lodging ($72,980).
Rhythm Pharmaceuticals, Inc. is associated with 3 products in the CMS Open Payments database.